Biomedical Science Letters

eISSN 2288-7415

Table. 1.

Association between ZEB1 and clinicopathological characteristics in lung cancer

Clinicopathological characteristics First progression survival Overall survival Post progression survival
N Hazard ratio P-value N Hazard ratio P-value N Hazard ratio P-value
SEX
Male 243 1.19 (0.85~1.7) 0.31 659 1.61 (1.3~2.0) 7.2e-0.6 82 1.49 (0.88~2.6) 0.14
Female 353 1.33 (0.85~2.1) 0.22 374 2.08 (1.5~2.9) 3.7e-0.5 56 1.45 (0.69~3.0) 0.32
STAGE
1 316 1.43 (0.91~2.2) 0.12 449 3.23 (2.3~4.5) 5.8e-12 76 2.44 (1.3~4.5) 0.0033
2 125 1.23 (0.72~2.1) 0.45 161 1.14 (0.72~1.8) 0.57 54 1.1 (0.55~2.2) 0.78
STAGE T
1 54 1.02 (0.27~3.8) 0.98 224 1.15 (0.78~1.7) 0.49 9 2.78 (0.44~1.8) 0.26
2 121 1.02 (0.55~1.9) 0.94 190 1.24 (0.85~1.82) 0.26 39 1.82 (0.85~3.8) 0.12
STAGE N
0 126 1.3 (0.65~2.6) 0.45 324 1.03 (0.75~1.4) 0.84 31 1.89 (0.81~4.4) 0.13
1 51 1.49 (0.6~3.72) 0.39 102 1.02 (0.62~1.68) 0.93 18 2.08 (0.61~7.1) 0.23
STAGE M
0 177 1.11 (0.64~1.9) 0.7 462 1.04 (0.82~1.3) 0.73 49 2.04 (1.0~4.1) 0.043

The clinicopathological characteristics of ZEB1 were analyzed using the Kaplan-Meier plotter. *P < 0.05. T, tumor; N, lymph node; M, distant metastases. Bold values indicate P < 0.05

Biomed Sci Letters 2022;28:9-24 https://doi.org/10.15616/BSL.2022.28.1.9
© 2022 Biomed Sci Letters